Search the Newsreel

Freenome targets lung screening gap; only about 18% of U.S. adults recommended get screened

Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen™ Lung test, a blood-based screening tool for lung cancer. The test is designed for high-risk adults aged 50-80 with a significant smoking history who are not currently undergoing recommended screening, aiming to address …

FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

Freenome has received FDA Breakthrough Device Designation for its investigational blood-based SimpleScreen™ Lung cancer screening test. This AI-powered multiomic test is designed for high-risk adults aged 50-80 who are not currently undergoing guideline-recommended lung cancer screening. The designation aims to accelerate the development and …

Freenome, Inc. (FRNM) stock price, news, quote and history

This article provides an overview of Freenome, Inc. (FRNM) stock performance, including its current price, news, and historical data. It details the company's stock price movement, key financial metrics like trailing total returns against the S&P 500, and lists relevant market data. The content …

Freenome Holdings Number of Employees 2026 | Employee Count & Headcount Data

Freenome Holdings, a Biotech and Healthcare Services company founded in 2014 and headquartered in Brisbane, California, had approximately 527 employees worldwide as of March 2026. This represents a 26.8% decline from 719 employees in 2023, though the company saw a slight increase from a …

FRNM | Freenome, Inc. Common stock Stock Data, Price & News

Freenome, Inc. (FRNM) Company Information

This article provides company information for Freenome, Inc. (FRNM), including its key details like ticker, exchange, founding year, industry, and market capitalization. It also outlines the data sources used for the company analysis, such as financial statements, analyst estimates, and market prices, and mentions …

Freenome secures FDA nod for blood-based colorectal cancer test

Freenome has received FDA approval for its blood-based colorectal cancer screening test, SimpleScreen CRC. Abbott will exclusively market the test in the U.S., adding it to its existing portfolio which includes the Cologuard stool test. The test is approved for adults 45 and older …

Freenome, Inc. (PCSC) CPO details common stock and multiple option grants

Freenome, Inc. (PCSC) director reports common stock and option stakes

Freenome, Inc. (FRNM) CFO discloses initial share and stock option positions

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

The FDA has approved Freenome's SimpleScreen™ CRC, a blood-based screening test for colorectal cancer, which Abbott will commercialize in the U.S. this fall. This approval provides a new, convenient screening option for adults aged 45 and older at average risk for CRC, a disease …

Operating cash flow per share of Freenome, Inc. – NASDAQ:FRNM

This article focuses on the operating cash flow per share of Freenome, Inc. (NASDAQ: FRNM). It appears to be a financial data page from TradingView, providing financial metrics for the biotechnology company. The page indicates market status and provides navigation to other financial details.

Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

Freenome, an early cancer detection company, has become publicly traded on the Nasdaq Capital Market under the ticker "FRNM" after completing its business combination with Perceptive Capital Solutions Corp. The company raised over $300 million in gross proceeds, which will fund the expansion of …